These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 18538450)

  • 1. Synthesis, antitubercular activity and docking study of novel cyclic azole substituted diphenyl ether derivatives.
    Kini SG; Bhat AR; Bryant B; Williamson JS; Dayan FE
    Eur J Med Chem; 2009 Feb; 44(2):492-500. PubMed ID: 18538450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and antitubercular activity of heterocycle substituted diphenyl ether derivatives.
    Kini SG; Bhat A; Pan Z; Dayan FE
    J Enzyme Inhib Med Chem; 2010 Oct; 25(5):730-6. PubMed ID: 20443682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel diphenyl ethers: design, docking studies, synthesis and inhibition of enoyl ACP reductase of Plasmodium falciparum and Escherichia coli.
    Chhibber M; Kumar G; Parasuraman P; Ramya TN; Surolia N; Surolia A
    Bioorg Med Chem; 2006 Dec; 14(23):8086-98. PubMed ID: 16893651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and antimycobacterial activity of azetidine-, quinazoline-, and triazolo-thiadiazole-containing pyrazines.
    Bonde CG; Peepliwal A; Gaikwad NJ
    Arch Pharm (Weinheim); 2010 Apr; 343(4):228-36. PubMed ID: 20205198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, in silico and in vitro evaluation of novel diphenyl ether derivatives as potential antitubercular agents.
    Tiwari AP; Sridhar B; Boshoff HI; Arora K; Gautham Shenoy G; Vandana KE; Varadaraj Bhat G
    Mol Divers; 2020 Nov; 24(4):1265-1279. PubMed ID: 31506871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational design and synthesis of novel diphenyl ether derivatives as antitubercular agents.
    Kar SS; Bhat G V; Rao PP; Shenoy VP; Bairy I; Shenoy GG
    Drug Des Devel Ther; 2016; 10():2299-310. PubMed ID: 27486307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel antitubercular compounds through hybrid virtual screening approach.
    Muddassar M; Jang JW; Hong SK; Cho YS; Kim EE; Keum KC; Oh T; Cho SN; Pae AN
    Bioorg Med Chem; 2010 Sep; 18(18):6914-21. PubMed ID: 20727773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, development, synthesis, and docking analysis of 2'-substituted triclosan analogs as inhibitors for Plasmodium falciparum enoyl-ACP reductase.
    Kapoor N; Banerjee T; Babu P; Maity K; Surolia N; Surolia A
    IUBMB Life; 2009 Nov; 61(11):1083-91. PubMed ID: 19859979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crystallographic and pre-steady-state kinetics studies on binding of NADH to wild-type and isoniazid-resistant enoyl-ACP(CoA) reductase enzymes from Mycobacterium tuberculosis.
    Oliveira JS; Pereira JH; Canduri F; Rodrigues NC; de Souza ON; de Azevedo WF; Basso LA; Santos DS
    J Mol Biol; 2006 Jun; 359(3):646-66. PubMed ID: 16647717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, anti-tuberculosis activity, and 3D-QSAR study of 4-(adamantan-1-yl)-2-substituted quinolines.
    Nayyar A; Monga V; Malde A; Coutinho E; Jain R
    Bioorg Med Chem; 2007 Jan; 15(2):626-40. PubMed ID: 17107805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological activity of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 2: 2'-substituted triclosan derivatives.
    Freundlich JS; Yu M; Lucumi E; Kuo M; Tsai HC; Valderramos JC; Karagyozov L; Jacobs WR; Schiehser GA; Fidock DA; Jacobus DP; Sacchettini JC
    Bioorg Med Chem Lett; 2006 Apr; 16(8):2163-9. PubMed ID: 16466916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and evaluation of novel molecules with a diphenyl ether nucleus as potential antitubercular agents.
    Yang Y; Wang Z; Yang J; Yang T; Pi W; Ang W; Lin Y; Liu Y; Li Z; Luo Y; Wei Y
    Bioorg Med Chem Lett; 2012 Jan; 22(2):954-7. PubMed ID: 22197389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of new enantiomerically pure azole derivatives as inhibitors of Mycobacterium tuberculosis.
    Castagnolo D; Radi M; Dessì F; Manetti F; Saddi M; Meleddu R; De Logu A; Botta M
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2203-5. PubMed ID: 19299129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based design of a novel class of potent inhibitors of InhA, the enoyl acyl carrier protein reductase from Mycobacterium tuberculosis: a computer modelling approach.
    Subba Rao G; Vijayakrishnan R; Kumar M
    Chem Biol Drug Des; 2008 Nov; 72(5):444-9. PubMed ID: 19012578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.
    Lu H; Tonge PJ
    Acc Chem Res; 2008 Jan; 41(1):11-20. PubMed ID: 18193820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel inhibitor of indole-3-glycerol phosphate synthase with activity against multidrug-resistant Mycobacterium tuberculosis.
    Shen H; Wang F; Zhang Y; Huang Q; Xu S; Hu H; Yue J; Wang H
    FEBS J; 2009 Jan; 276(1):144-54. PubMed ID: 19032598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational design of InhA inhibitors in the class of diphenyl ether derivatives as potential anti-tubercular agents using molecular dynamics simulations.
    Kamsri P; Koohatammakun N; Srisupan A; Meewong P; Punkvang A; Saparpakorn P; Hannongbua S; Wolschann P; Prueksaaroon S; Leartsakulpanich U; Pungpo P
    SAR QSAR Environ Res; 2014; 25(6):473-88. PubMed ID: 24785640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of the tautomeric forms of isoniazid-NAD adducts to the active site of the Mycobacterium tuberculosis enoyl-ACP reductase (InhA): a theoretical approach.
    Stigliani JL; Arnaud P; Delaine T; Bernardes-Génisson V; Meunier B; Bernadou J
    J Mol Graph Model; 2008 Nov; 27(4):536-45. PubMed ID: 18955002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of 1-[3-(4-benzotriazol-1/2-yl-3-fluoro-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-3-substituted-thiourea derivatives as antituberculosis agents.
    Dixit PP; Patil VJ; Nair PS; Jain S; Sinha N; Arora SK
    Eur J Med Chem; 2006 Mar; 41(3):423-8. PubMed ID: 16494970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis.
    Sullivan TJ; Truglio JJ; Boyne ME; Novichenok P; Zhang X; Stratton CF; Li HJ; Kaur T; Amin A; Johnson F; Slayden RA; Kisker C; Tonge PJ
    ACS Chem Biol; 2006 Feb; 1(1):43-53. PubMed ID: 17163639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.